INCY News and Press, Incyte Corporation From 02/09/22

Incyte (INCY -2.2%) has extended its post-market losses on Wednesday despite recording better than expected revenue for Q4 2021. Its blockbuster JAK inhibitor, JAKAFI/JAKAVI (ruxolitinib), brought $592M in net product revenue during the quarter with ~15% YoY growth expanding the yearly net pr...

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Incyte Corporation (INCY) Q4 2021 Earnings Conference Call February 8, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman, President and Chief Executive Officer Barry Flannelly – Executive Vice President and Gener...

Incyte's (NASDAQ:INCY) Q4 2021 revenue beat was helped in large part by a 15% year-over-year increase in sales of JAK inhibitor Jakafi (ruxolitinib). Shares are down 1.7% pre-market. Overall, reevenue rose ~9% YoY to $862.5M. Jakafi sales rose to $592M. Incyte also launched Opz...

Incyte press release (NASDAQ:INCY): Q4 EPS of $0.10 may not be comparable to consensus of $0.86. Revenue of $862.5M (+9.2% Y/Y) beats by $49.12M. Total product and royalty revenues of $813 million (+20%) in Q4’21 Jakafi® (ruxolitinib) net product revenues of $592 million (+15...

Total product and royalty revenues of $813 million (+20%) in Q4’21 and $2.891 billion (+17%) in FY’21 Jakafi ® (ruxolitinib) net product revenues of $592 million (+15%) in Q4’21 and $2.135 billion (+10%) in FY’21; Jakafi guidance range of $2.3 ...

Incyte (NASDAQ:INCY) is scheduled to announce Q4 earnings results on Tuesday, February 8th, before market open. The consensus EPS Estimate is $0.86 (-7.5% Y/Y) and the consensus Revenue Estimate is $813.38M (+3.0% Y/Y). Over the last 2 years, INCY has beaten EPS estimates 75% of the time and ...

Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis PR Newswire INDIANAPOLIS , Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 deve...

Incyte (Nasdaq:INCY) today announced updates regarding the clinical development of parsaclisib, the Company’s next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), and MCLA-145, its CD137/PD-L1 bispecific antibody co-developed under a global collab...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific...